RSS2.0

R) Significantly Delayed Permanent ...

Tuesday, May 1, 2007

Bayer HealthCare Pharmaceuticals announced today new data, which show that immediate initiation of Betaseron® treatment in patients with a first event suggestive of multiple sclerosis can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale by 40 percent over three years compared to delayed treatment.
From: biz.yahoo.com

0 comments: